{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:53:40Z","timestamp":1777953220635,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction\/Aims<\/jats:title>\n                    <jats:p>High\u2010concentration capsaicin topical system (HCCTS) is an established treatment for painful diabetic peripheral neuropathy (PDPN). The PACE primary analysis showed that HCCTS\u2009+\u2009standard of care (SOC) was not associated with deterioration in nerve function compared with SOC alone over 52\u2009weeks. This post hoc analysis of PACE evaluated sensory function changes in the feet after repeated 30\u2010min HCCTS treatments\u2009+\u2009SOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sensory function was assessed using the Brief Sensory Pain Examination (BSPE) alongside the Norfolk Quality of Life\u2013Diabetic Neuropathy (QOL\u2010DN) questionnaire and its small\u2010 and large\u2010fiber subscales. Analysis 1 descriptively assessed shifts in sensory test results over 12\u2009months in patients receiving one to seven 30\u2010min HCCTS treatments\u2009+\u2009SOC. Analysis 2 statistically compared mean sensory scores over 12\u2009months with HCCTS\u2009+\u2009SOC versus SOC alone in patients with below\u2010normal baseline sensory function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analysis 1 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009156) showed that repeated HCCTS treatments were associated with shifts from below\u2010normal to normal sensory function at Month 12 in 21.1%, 26.4%, and 22.8% of heat, cold, and sharp tests, respectively. Analysis 2 (HCCTS\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200988; SOC\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200989) demonstrated significant improvements with HCCTS\u2009+\u2009SOC versus SOC alone in BSPE heat (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), sharp (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048), vibration (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008), and Norfolk QOL\u2010DN total (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and large\u2010fiber subscale scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Repeated 30\u2010min HCCTS treatments\u2009+\u2009SOC improved peripheral sensory function over 12\u2009months in PDPN patients with baseline sensory deficits. If confirmed in dedicated trials, sensory improvements may reduce diabetic foot complications by restoring protective sensation, possibly via neuroregenerative effects of HCCTS reported elsewhere.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mus.70237","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:20:21Z","timestamp":1775265621000},"page":"1109-1117","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Capsaicin (8%) Topical System on Sensory Function in Patients With Diabetic Peripheral Neuropathy: Analysis of the\n                    <scp>PACE<\/scp>\n                    Study"],"prefix":"10.1002","volume":"73","author":[{"given":"Nathaniel P.","family":"Katz","sequence":"first","affiliation":[{"name":"Ein Sof Innovation Ltd.  Wellesley Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Allen","sequence":"additional","affiliation":[{"name":"Averitas Pharma, Inc.  Morristown New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Carnevale","sequence":"additional","affiliation":[{"name":"Averitas Pharma, Inc.  Morristown New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizandra","family":"Marcondes","sequence":"additional","affiliation":[{"name":"Averitas Pharma, Inc.  Morristown New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Neurology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"US Food and Drug Administration \u201cQUTENZA (Capsaicin) Patch. US Prescribing Information \u201d2020 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022395s018lbl.pdf."},{"key":"e_1_2_13_3_1","unstructured":"European Medicines Agency \u201cQUTENZA (Capsaicin). EU Summary of Product Characteristics \u201daccessed January 16 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/qutenza\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107743"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aer260"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.998904"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.09.008"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.09.019"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh175"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0752-7"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2005.7.497"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.703"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002735"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080008"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12704"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S526968"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-022-01104-1"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020165"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2013.02.014"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.70237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:35:46Z","timestamp":1777905346000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.70237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/mus.70237"],"URL":"https:\/\/doi.org\/10.1002\/mus.70237","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}